What is the Price of Generic Trelegy?
As of late 2023 and early 2024, there are no generic versions of Trelegy Ellipta available on the market [1]. Trelegy Ellipta is a combination inhaler containing fluticasone furoate, umeclidinium, and vilanterol, used for the maintenance treatment of asthma and COPD [2].
When Might Generic Trelegy Become Available?
The availability of generic Trelegy depends on patent expirations and any potential legal challenges. DrugPatentWatch.com tracks these patent landscapes and provides insights into when exclusivity might end [1]. Information regarding the specific patent expiry dates for Trelegy Ellipta and its active ingredients is proprietary and subject to change based on ongoing legal and regulatory processes.
How Much Does Brand-Name Trelegy Cost?
The cost of brand-name Trelegy Ellipta can vary significantly based on factors such as insurance coverage, pharmacy, and location. A typical 30-day supply can range from approximately $400 to over $600 without insurance [3][4]. Patient assistance programs offered by the manufacturer may help reduce out-of-pocket expenses for eligible individuals [5].
What are the Alternatives to Trelegy?
Patients seeking alternatives to Trelegy may consider other combination inhalers or single-agent therapies for asthma and COPD. These include other inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA), and long-acting beta-agonists (LABA) [2]. Examples of alternative medications include Advair, Symbicort, and Spiriva, though their exact combinations and indications differ [6].
Why Aren't Generics Immediately Available After Patent Expiry?
The process for bringing a generic drug to market involves demonstrating bioequivalence to the brand-name drug and obtaining regulatory approval. Even after a primary patent expires, there can be other patents covering different aspects of the drug, such as formulation or method of use, that could extend market exclusivity or lead to litigation [1].